Company profile
Crinetics Pharmaceuticals, Inc.
NASDAQ: CRNX · Healthcare · Biotechnology
#662 of 1,422 Healthcare companies by revenuetop-decile growth
EA Score
53DFH 47DQ 57GM 55SS 72
v0.1 · 65/100 weight · provisional
↑ revenue growth (YoY), Altman-Z · ↓ operating margin, net margin
Methodology →Revenue TTM
$18.1M
Rev growth YoY (TTM)
+2277.5%
Net income (FY)
-$465.3M
Employees
594
as of 2026-08-07
Market cap
$8.9B
as of 2026-08-07
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$7.7M$7.7M2025
Net income-$465.3M-$465.3M2025
Operating income-$516.8M-$516.8M2025
Total assets$1.1B$1.1B2025
Liabilities$134.2M$134.2M2025
Equity$992.1M$992.1M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY25
FY25
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product70%
License and Service30%
By geography
Not disclosed.
The read
What is Crinetics Pharmaceuticals, Inc.’s revenue?
Crinetics Pharmaceuticals, Inc. booked $7.7M in FY2025 revenue, growing 641% year over year — faster than 95% of Healthcare companies we track, at a -6046.2% net margin.
Peers · Healthcare
Cogent Biosciences, Inc.48DAclaris Therapeutics, Inc.47DPulmatrix, Inc.46DBolt Biotherapeutics, Inc.39DBeyond Air, Inc.42DAmazonas Florestal, Ltd——Neighbors
San Diego →Key facts
CEOR. Scott Struthers
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Diego, CA
ExchangeNASDAQ: CRNX
Employees594
IPO date2018-07-18
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.